Smith MR - Search Results

1

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Armstrong AJ, et al. Among authors: smith mr. Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. Ann Oncol. 2018. PMID: 29088323 Free PMC article. No abstract available.

2

Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer.

Smith MR, Kantoff PW. Smith MR, et al. Semin Oncol. 1995 Dec;22(6):625-32. Semin Oncol. 1995. PMID: 8539637 Review.

3

Saving millions: the case for the Assessment Centre in Health Management.

Smith M, George D. Smith M, et al. N Z Hosp. 1988 Jan-Feb;40(1):5-6. N Z Hosp. 1988. PMID: 10287699 No abstract available.

4

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al. Bubley GJ, et al. Among authors: smith mr. J Clin Oncol. 1999 Nov;17(11):3461-7. doi: 10.1200/JCO.1999.17.11.3461. J Clin Oncol. 1999. PMID: 10550143

5

Genitourinary malignancies.

Smith MR, Kantoff P. Smith MR, et al. Cancer Chemother Biol Response Modif. 1999;18:394-417. Cancer Chemother Biol Response Modif. 1999. PMID: 10800495 Review. No abstract available.

6

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.

Fizazi K, Ducreux M, Ruffié P, Bonnay M, Daniel C, Soria JC, Hill C, Fandi A, Poterre M, Smith M, Armand JP. Fizazi K, et al. J Clin Oncol. 2000 Jun;18(11):2293-300. doi: 10.1200/JCO.2000.18.11.2293. J Clin Oncol. 2000. PMID: 10829050 Clinical Trial.

7

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Mueller E, et al. Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5. doi: 10.1073/pnas.180329197. Proc Natl Acad Sci U S A. 2000. PMID: 10984506 Free PMC article. Clinical Trial.

8

Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.

Smith MR, Kaufman D, Oh W, Guerin K, Seiden M, Makatsoris T, Manola J, Kantoff PW. Smith MR, et al. Cancer. 2000 Oct 15;89(8):1824-8. doi: 10.1002/1097-0142(20001015)89:8<1824::aid-cncr24>3.0.co;2-r. Cancer. 2000. PMID: 11042579 Clinical Trial.

9

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H. Kelly WK, et al. J Clin Oncol. 2001 Jan 1;19(1):44-53. doi: 10.1200/JCO.2001.19.1.44. J Clin Oncol. 2001. PMID: 11134194 Clinical Trial.

10

Low bone mineral density in hormone-naïve men with prostate carcinoma.

Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Smith MR, et al. Cancer. 2001 Jun 15;91(12):2238-45. Cancer. 2001. PMID: 11413511

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,175 results

Search Page

Filters